Effect of hormone replacement therapy on growth hormone stimulation in women with premature ovarian failure.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.

To assess the effect of oral hormone replacement therapy (HRT) on body weight, insulin-like growth factor I (IGF-I), and GH response to exogenous GHRH [corrected] in women with premature ovarian failure (POF) [corrected].

Who Took Part

The study group was 24 volunteers.

By PubMed's age tags, the people studied were adults, women only.

Twenty-four women with POF (study group) and 24 volunteers with normal ovarian cycles (control group).

Pituitary GHRH [corrected] stimulation was performed in all women at study entry and in patients with POF after 1, 6, and 12 months of standard oral HRT.

How the Study Was Run

Blood samples were collected from 15 minutes before to 120 minutes after GHRH administration [corrected].

Body weight also was evaluated.

What Was Measured

PubMed files the paper under topics including Estradiol, Estrogen Replacement Therapy, Follicle Stimulating Hormone, Gonadotropin-Releasing Hormone, Human Growth Hormone, Insulin-Like Growth Factor I and Primary Ovarian Insufficiency.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 24 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1997 (Fertility and sterility), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.